Japan to Launch Public Support System for Elderly Living Alone; Hospitalization, Nursing Homes, Funeral Arrangements Covered
The framework would cover hospital admission, entry into nursing homes and post-mortem procedures such as funerals.
The ministry aims to launch the program in fiscal 2027 with an eye toward revising the Social Welfare Law next year.
While private services for seniors without families do exist, high costs restrict access to only a limited number of users. Nationwide social welfare councils also offer money-management support, but those programs are currently limited to people with dementia and similar conditions. The ministry concluded that 'a broad-based system is needed to support the final stage of life for single older adults.'
The support will likely include acting on behalf of the elderly in administrative procedures for hospital admission or nursing home placement, as well as serving as an emergency contact. Posthumous affairs are expected to cover tasks such as funeral arrangements, burial and clearing out the deceased's home. The support providers will include local social welfare councils and nonprofit organizations. Fees will be based on income, with free or low-cost options available for low-income individuals.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NHK
2 days ago
- NHK
Clinics across Japan report increase in COVID-19 patients
Medical institutions in Japan have been seeing more people infected with the coronavirus, with the average number of patients per institution topping five for the first time since February. The Japanese health ministry on Friday released a weekly report on the number of COVID-19 patients who visited about 3,000 clinics across the country for the week ending Sunday. The ministry said 21,365 people had been confirmed infected. The figure was an increase of 5,441 people from a week before. The average number of coronavirus patients per institution was 5.53. That's 1.34 times higher than the previous week and marks the seventh consecutive weekly increase. The average rose in all of Japan's 47 prefectures except Okinawa. Miyazaki had the highest number at 14.07, followed by Okinawa with 12.73, Kagoshima with 12.68, Kumamoto with 9.58 and Saga with 8.75. Reports from about 500 medical institutions showed 1,501 coronavirus patients had been hospitalized during the week. That's 314 more than the previous week. Health ministry officials say an increase in the number of COVID-19 patients has been seen every summer. The officials urge people to take preventive measures, such as washing hands and ventilating indoor spaces. They also recommend wearing masks when meeting elderly people and those with underlying conditions.
Yomiuri Shimbun
2 days ago
- Yomiuri Shimbun
Japan Drugmaker Applies for Approval of Stem Cell-Derived Parkinson's Treatment; Aims to Obtain Approval Within FY25
Sumitomo Pharma Co., a major drugmaker, announced on Tuesday that it has applied to the Health, Labor and Welfare Ministry for approval to produce and sell a regenerative medical product for the treatment of Parkinson's disease. The drug contains dopamine-producing nerve cells derived from induced pluripotent stem (iPS) cells and is transplanted directly into patients' brains. It is the second application to the ministry for the approval of a regenerative medicine derived from iPS cells. Parkinson's is caused by a reduction in the nerve cells which produce dopamine, a neurotransmitter produced in the brain involved in body movement. Patients with the disease develop such symptoms as tremors in the hands or legs and have difficulty walking. In Japan, there are an estimated 250,000 people with Parkinson' treatment method was jointly developed by Sumitomo Pharma and a team of researchers from Kyoto University. These researchers conducted clinical tests from 2018 to 2021. In the tests, 5 million to 10 million nerve cells were derived from iPS cells taken from healthy people and transplanted into the patients' brains. The researchers published the results in the science journal Nature in April this year, stating that four of the six patients experienced an improvement in their symptoms. Sumitomo Pharma, which is in charge of producing the nerve cells, applied for the ministry's approval based on the test results. The regenerative medicine is covered by the government's special screening designation system, in which priority is given to applications for revolutionary medical treatments originating in Japan. According to the ministry, the length of time necessary for the screening, which is usually about a year, will likely be shortened. Sumitomo Pharma President Toru Kimura said, 'We will make utmost efforts to obtain approval by the end of this fiscal year. We want to respond at maximum speed [for the ministry's screening].' The previous application for production and sales of a regenerative medicine derived from iPS cells was submitted by Cuorips Inc., an Osaka-based startup, in April. The startup makes sheets of heart muscle cells for patients with serious heart diseases.
Japan Times
6 days ago
- Japan Times
Kobayashi Pharmaceutical chairman vows corporate culture reform
Japan's Kobayashi Pharmaceutical will accelerate efforts to reform its corporate culture marked by workers' reliance on top management, Chairman Yoshihito Ota has said. A major problem the drug and supplement maker must address is the "strong tendency to depend on top management," seen among its employees, Ota said in a recent interview. Ota took office in March after being invited from outside the Osaka-based company, following a massive health hazard caused by supplements containing beni kо̄ji red yeast rice ingredients that came to light early last year. Led by top executives mainly from the founding family, Kobayashi Pharmaceutical achieved net profit growth for over 20 years from its stock market listing in 1999, until the beni kо̄ji scandal emerged. For many employees, "it was easier to work if they depended on someone rather than asserting themselves" during the period of strong growth, Ota said. As the company focused on generating profits, capital investment plans were often delayed, leaving the manufacturing staff exhausted, but the division did not request an improvement, according to Ota. "The manufacturing division weakened," while the marketing division was strong, he continued. Probes into the beni kо̄ji scandal have found that culture drums in a company factory had cracks due to aging, indicating the possibility that mold spores may have entered the drums through the cracks, allowing the substance that caused the health hazard to generate inside the drums. "It's best to renew facilities systematically," Ota said, underscoring his intent to strengthen the manufacturing division. Saying that quality control has not been unified across the entire group, Ota also emphasized, "We'll carry out structural reform of the entire manufacturing division." Before joining Kobayashi Pharmaceutical, Ota was involved in the reconstruction of Japan Airlines after its 2010 bankruptcy, as a close aide to the late Kyocera founder Kazuo Inamori, who led the airlines' turnaround. Under Ota, Kobayashi Pharmaceutical regularly holds a leadership workshop for senior officials to foster a culture where employees make decisions and take action independently. "The corporate culture will not change unless the older generation changes, " he said.
